Jose Florez and his group have contributed to the performance and analysis of high-throughput genomic studies in type 2 diabetes, related traits and complications, in international consortia such as MAGIC, GENIE, DIAGRAM, T2D-GENES, AMP-T2D and SIGMA. He leads the genetic research initiative of the Diabetes Prevention Program, and is the PI of the Study to Understand the Genetics of the Acute Response to Metformin and Glipizide in Humans (SUGAR-MGH) and other pharmacogenetic studies at MGH.